pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Obesity · news · pharmadog
← back to Obesity
News mentioning Obesity
549
stories
10d
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
biospace
11d
Chutes & Ladders—Travere chief makes way for former Amicus CEO
fiercebiotech
11d
STAT+: Indonesian ruling against ‘patent evergreening’ by pharma industry sends critical message, patient advocates say
stat
11d
Lilly’s latest China drug deal; Immunovant’s setback in lupus
biopharma dive
11d
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
biospace
11d
Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs
biospace
11d
Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugs
fiercebiotech
11d
Enveda, an AI drugmaker, banks $311M in venture funding
biopharma dive
12d
AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease push
biospace
12d
STAT+: Flagship gets a Pentagon contract
stat
12d
STAT+: Pharmalittle: We’re reading about a closing loophole for importing meds, European competitiveness, and more
stat
12d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
12d
Enveda reaps $311M series E to feed ambition to become a ‘household name’
fiercebiotech
12d
Opinion: Mentally ill women deserve more support to have children
stat
12d
STAT+: HHS unveils new initiatives to reduce animal testing in drug development
stat
13d
STAT+: Did the Trump administration just cut Novo a huge financial win?
stat
13d
Viking shares surge on updated obesity drug data
biopharma dive
13d
Viking achieves 'maintenance trifecta' as GLP-1/GIP dual agonist exceeds expectations
biospace
13d
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
biospace
13d
Viking touts once-a-month weight loss maintenance data
endpoints
13d
Lilly presents early data supporting GLP-1/GIP candidate's potential in depression, alcohol use disorder
biospace
13d
STAT+: Novo may be getting a better deal than expected with Medicare’s Bridge program
stat
13d
2026 IPO blitz continues with 4 new biotech filings
biospace
13d
Novo’s workforce reduction climbs to 13,000 to fuel R&D work
biospace
13d
Roche’s Carmot asset normalizes blood sugar, cuts weight in Phase 2 diabetes trial
biospace
13d
STAT+: Pharmalittle: We’re reading about pharma seeking to protect China deals, a Roche obesity drug, and more
stat
13d
Siemens Healthineers and Novo team up on fatty liver disease awareness, testing
fiercebiotech
13d
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
fiercebiotech
14d
Novo talks up drug launches in effort to win back investors
biopharma dive
14d
Novo offers low-dose CagriSema data as approval decision looms
endpoints
← prev
page 3 of 19
next →
